ILUMYA® (tildrakizumab-asmn) approved in the U.S. for the Treatment of Adults with Active Psoriatic Arthritis
IL-23 inhibitor approved exclusively for healthcare provider-administered treatment Expands use of ILUMYA beyond moderate-to-severe plaque psoriasis strengthening Sun Pharma's portfolio in psoriatic disease MUMBAI, India and PRINCETON, N.J., Oct. 30, 2026 /PRNewswire/ -- Sun...
Read the full story on PR Newswire → Opens the original article on www.prnewswire.comSummary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.